Apellis Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.24, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Apellis Pharmaceuticals Inc 's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 113 days, from 105 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 467 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 513 to 3065.

What is Receivable Turnover Ratio?
What is Apellis Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

APLS Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	87.17 %	38.24 %	23.84 %	-29.66 %	-12.17 %
Y / Y Revenue Change	60.85 %	-5.94 %	132.98 %	-10.61 %	-3.21 %
Receivable Turnover Ratio (TTM)	3.24	3.46	3.84	3.04	2.86
APLS's Total Ranking	# 3065	# 513	# 2764	# 1033	# 1037
Accounts Receivable average collection period days	113	106	95	120	127
Seq. Receivable Change	20.23 %	5.99 %	61.37 %	-8.98 %	-11.2 %
Seq. Revenue Change	34.21 %	-56.41 %	156.92 %	7.01 %	-21.52 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 147
Healthcare Sector	# 468
Overall Market	# 3065

Receivable Turnover Ratio Statistics
High	Average	Low
15.66	5.9	2.65
(Mar 31 2022)		(Jun 30 2024)

APLS Company Profile • Back to APLS Efficiency Comparisons • Compare APLS Receivables Turnover Ratio to its Competitors

Financial Statements
Apellis Pharmaceuticals Inc 's Accounts Receivable	$ 440 Millions	Visit APLS's Balance sheet
Apellis Pharmaceuticals Inc 's Sales TTM	$ 1,105 Millions	Visit APLS's Income Statement
Sources of APLS's Revenues		Visit APLS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
APLS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
APLS's Growth Rates	APLS's Roa	APLS's Inventory Turnover Ratio	APLS's Dividend Comparisons
APLS's Profitability Ratios	APLS's Roi	APLS's Asset Turnover Ratio	APLS's Dividend Growth
APLS's Valuation Ratios	APLS's Roe	APLS's Financial Strength Ratios	APLS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Merit Medical Systems Inc	6.90	$ 1,542.047 Millions	$ 223.614 Millions
Solventum Corporation	6.89	$ 8,262.000 Millions	$ 1,198.750 Millions
Edwards Lifesciences Corporation	6.85	$ 6,303.300 Millions	$ 920.125 Millions
Fate Therapeutics Inc	6.83	$ 6.316 Millions	$ 0.924 Millions
Neuropace Inc	6.83	$ 98.926 Millions	$ 14.490 Millions
Ceribell Inc	6.83	$ 94.389 Millions	$ 13.828 Millions
Arcturus Therapeutics Holdings Inc	6.83	$ 54.710 Millions	$ 8.016 Millions
Schrodinger Inc	6.81	$ 254.905 Millions	$ 37.438 Millions
Genedx Holdings Corp	6.81	$ 442.908 Millions	$ 65.066 Millions
Catheter Precision Inc	6.78	$ 1.108 Millions	$ 0.164 Millions
Carlisle Companies Incorporated	6.77	$ 4,976.200 Millions	$ 735.475 Millions
3m Company	6.75	$ 25,024.000 Millions	$ 3,706.000 Millions
Seastar Medical Holding Corp	6.73	$ 1.436 Millions	$ 0.214 Millions
Insmed Inc	6.71	$ 737.256 Millions	$ 109.926 Millions
Nuo Therapeutics Inc	6.70	$ 4.036 Millions	$ 0.602 Millions
Myriad Genetics Inc	6.70	$ 828.000 Millions	$ 123.525 Millions
Phibro Animal Health Corporation	6.70	$ 1,500.123 Millions	$ 223.852 Millions
Ufp Technologies Inc	6.68	$ 608.621 Millions	$ 91.103 Millions
Pulmonx Corporation	6.68	$ 87.841 Millions	$ 13.151 Millions
Beone Medicines Ltd	6.68	$ 5,737.861 Millions	$ 859.289 Millions
Blue Water Vaccines Inc	6.68	$ 0.735 Millions	$ 0.110 Millions
Avanos Medical Inc	6.67	$ 714.200 Millions	$ 107.125 Millions
Stryker Corp	6.66	$ 25,270.000 Millions	$ 3,792.750 Millions
Moderna Inc	6.66	$ 2,225.000 Millions	$ 334.250 Millions
Iradimed Corporation	6.65	$ 86.282 Millions	$ 12.966 Millions
Envista Holdings Corporation	6.63	$ 2,807.800 Millions	$ 423.725 Millions
Bionano Genomics Inc	6.62	$ 28.738 Millions	$ 4.338 Millions
Syndax Pharmaceuticals Inc	6.62	$ 217.174 Millions	$ 32.817 Millions
Liquidia Corporation	6.62	$ 288.065 Millions	$ 43.544 Millions
Cvrx inc	6.59	$ 57.909 Millions	$ 8.783 Millions

Date modified: 2026-08-30T14:57:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.